Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
31.84
+1.01 (3.28%)
May 29, 2025, 4:00 PM - Market closed
Agios Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 7 professional analysts, the 12-month price target for Agios Pharmaceuticals stock ranges from a low of $46 to a high of $71. The average analyst price target of $56 forecasts a 75.88% increase in the stock price over the next year.
Price Target: $56.00 (+75.88%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Agios Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Buy Maintains $74 → $71 | Buy | Maintains | $74 → $71 | +122.99% | May 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $58 | Strong Buy | Reiterates | $58 | +82.16% | Feb 24, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Dec 18, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $55 → $57 | Buy | Maintains | $55 → $57 | +79.02% | Dec 10, 2024 |
| Scotiabank | Scotiabank | Buy Maintains $53 → $75 | Buy | Maintains | $53 → $75 | +135.55% | Dec 9, 2024 |
Financial Forecast
Revenue This Year
46.51M
from 36.50M
Increased by 27.43%
Revenue Next Year
134.79M
from 46.51M
Increased by 189.81%
EPS This Year
-7.33
from 11.64
EPS Next Year
-6.86
from -7.33
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 58.8M | 218.7M | 446.3M | ||
| Avg | 46.5M | 134.8M | 325.9M | ||
| Low | 38.8M | 91.1M | 171.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 61.1% | 370.2% | 231.1% | ||
| Avg | 27.4% | 189.8% | 141.8% | ||
| Low | 6.3% | 96.0% | 27.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -7.09 | -5.65 | -2.15 | ||
| Avg | -7.33 | -6.86 | -4.37 | ||
| Low | -7.55 | -8.18 | -8.82 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.